Cancer Research Institute's video: Imaging in Immunotherapy: Using PET Scans to Guide Cancer Treatment with Kim A Margolin M D

In this webinar for patients and caregivers, Kim A. Margolin, M.D., discusses antibody-based imaging strategies that help doctors visualize patients’ tumors and immune cells in real-time via PET scans. https://www.cancerresearch.org/events/webinars/cancer-pet-scan-tumor-imaging-treatment-decisions Imagine a safe, non-invasive method that would allow doctors to predict if patients will respond to certain immunotherapies. If oncologists could measure certain factors (such as the presence of T cells or the expression of PD-L1 within tumors) before treatment, they could design better treatment regimens for patients. If oncologists could measure these factors during treatment, they could determine if or how patients are responding. Kim A. Margolin, M.D., is a clinical professor in the department of medical oncology and therapeutics research at the City of Hope National Medical Center, where she serves as a principal investigator on a phase 2 trial that is using novel, immune-based imaging in patients with metastatic cancer who are being treated with immunotherapy and chemotherapy. Dr. Margolin is triple board-certified in internal medicine with subspecialties in medical oncology and hematology and is a fellow of the American College of Physicians. She has been the Chair of the Cancer Education Committee and a member of the Nominating Committee of the American Society of Clinical Oncology (ASCO) and previously served as a member of the Oncologic Drug Advisory Committee (ODAC) of the FDA. Dr. Margolin is also an active member of several foundations and federal grant review committees, including the Melanoma Research Alliance, Department of Defense, and Melanoma Research Foundation. Among her 180 peer-reviewed articles, 60 invited reviews or editorials, and 16 book chapters, her most recent work has been in the area of melanoma metastatic to the brain and immunotherapy strategies for melanoma and other skin cancers. Previously, Dr. Margolin earned her undergraduate degree summa cum laude from the University of California, Los Angeles, graduating Phi Beta Kappa, then went on to receive her medical degree from Stanford University School of Medicine. After an internal medicine residency at Yale-New Haven Hospital in New Haven, CT, Dr. Margolin began her fellowship in hematology/oncology at the University of California, San Diego School of Medicine, and completed the fellowship in medical oncology and hematology and bone marrow transplantation at the City of Hope. She remained on the City of Hope faculty in both departments for 25 years prior to her recruitment to Seattle. This webinar is a special edition of CRI's "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is hosted by our director of marketing and communications, Brian Brewer. This webinar is made possible with generous support from ImaginAb. https://www.cancerresearch.org/events/webinars Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.